#United States #Fort Lee, NJ #Kedrion Biopharma #Ryplazim #PLGD-1

Kedrion Biopharma Expands Distribution Network for Ryplazim

Kedrion Biopharma Inc., a leader in biopharmaceutical products, has announced a significant expansion of its distribution network for Ryplazim, a plasma-derived human plasminogen. This treatment is specifically indicated for patients diagnosed with plasminogen deficiency type 1 (PLGD-1).

The expansion is a crucial development, enabling better access to this vital medication across the United States. PLGD-1 is a serious condition characterized by the formation of abnormal fibrin-rich lesions on mucosal surfaces, resulting in potentially severe complications such as vision impairment, hearing loss, airway obstruction, and even infertility if left untreated. Ryplazim stands out as the only FDA-approved therapy available for individuals suffering from this rare condition.

Recent FDA Approvals Enable Expansion

The impetus for this distribution network enhancement comes after the FDA granted approval for the technology transfer and an expansion of the manufacturing capacity for Ryplazim. This positive regulatory development has allowed Kedrion to broaden its prior limited distribution channels, ensuring that a greater number of patients will be able to receive this essential medication.

With these changes, Kedrion has welcomed a new distribution partner, CuraScript SD, alongside existing partners FFF Enterprises and The Alliance Pharmacy. Additionally, two new specialty pharmacies—CVS Health and Soleo Health—have joined the initiative, thereby boosting the points of access for patients in need of Ryplazim. Nufactor continues to be part of the enhanced distribution network. This collaborative effort underscores Kedrion's steadfast commitment to improving patient care and expanding access to critical therapies.

Enhancing Patient Care and Support

Bob Rossilli, Chief Commercial Officer and Global Business Manager for Kedrion, articulated the importance of this distribution network expansion, stating that it not only allows for greater volumes of Ryplazim to be manufactured but also emphasizes the need for educating healthcare providers on the identification and diagnosis of PLGD-1 patients. Once a patient is diagnosed, robust infrastructure must be in place to ensure timely delivery of the medication and to ultimately enhance patient care.

"Every patient should have a reliable access point for the Therapy they may require throughout their lives. This expanded distribution network is a crucial step toward making that goal a reality," Rossilli noted.

Importance of Access to Rare Disease Medications

Access to necessary medications for rare diseases can often be fraught with challenges, but Kedrion's recent efforts appear aimed at dismantling many of these barriers. The enhancements to the distribution network are seen as revitalizing efforts toward elevating availability and ensuring that those in need are not left waiting and wondering about access to their treatments.

To learn more about Ryplazim and the potential benefits it offers to patients with PLGD-1, interested parties are encouraged to visit www.Ryplazim.com for additional information.

Kedrion’s commitment to patient-centered care is underscored by their ongoing efforts and innovations in the field of biopharmaceuticals. The company specializes in both research and production of plasma-derived therapeutic products that tackle serious diseases—including but not limited to PLGD-1, hereditary factor X deficiency, and hemophilia.

This expansion not only reflects Kedrion’s dedication to improving treatment outcomes for patients but also signifies a larger trend towards collaborative efforts in rare disease management and support. With a robust portfolio of 38 life-saving products distributed in over 100 countries, Kedrion continues to demonstrate its role as a pivotal player in global healthcare.

For more information on Kedrion Biopharma and its commitment to keeping life flowing through innovative health solutions, visit Kedrion Biopharma - Keep Life Flowing.